ACB Earnings Prediction
The chart below shows how ACB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ACB sees a -1.59% change in stock price 10 days leading up to the earnings, and a -3.72% change 10 days following the report. On the earnings day itself, the stock moves by +4.72%. This data can give you a slight idea of what to expect for the next quarter's release.
ACB Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
88.20M
37.01%
8.72%
Gross Margin
8.09%
193.85%
717.17%
Operating Margin
-36.25%
-46.11%
-27.21%
Net Margin
35.41%
233.62%
1618.93%
EPS
0.57
258.33%
-359.09%
No Data Available
ACB Earnings Analysis
Aurora Cannabis Inc Corporation (ACB.O) Earnings Conference Call
Positive
Earnings Per Share Surprise: Reported EPS of $0.58, significantly exceeding expectations of $-0.09.
Net Revenue Surge: Overall net revenue grew 37% to $88.2 million, driven by a 51% increase in global medical cannabis revenue.
International Cannabis Revenue Surge: International medical cannabis revenue surged 112%, now comprising 60% of global medical cannabis net revenue, up 300 basis points sequentially.
Record Adjusted EBITDA Growth: Adjusted EBITDA reached a record $23.1 million, reflecting a 316% increase year-over-year, marking the ninth consecutive quarter of positive adjusted EBITDA.
Free Cash Flow Improvement: Generated $27 million in positive free cash flow, a significant improvement from a negative free cash flow of $4.7 million in the prior year.
Negative
Cannabis Revenue Decline: Consumer cannabis net revenue decreased to $9.9 million, down from $11.6 million in the year ago period, reflecting a strategic shift towards higher-margin medical cannabis.
Consumer Cannabis Margin Decline: Adjusted gross margins for consumer cannabis fell to 26% from 29% year-over-year, indicating a decline in profitability for this segment.
SG&A Expense Increase: Consolidated adjusted SG&A expenses increased by 12.6% to $31.3 million compared to the year ago period, which may pressure overall profitability despite revenue growth.
Seasonal Revenue Volatility: The Bevo plant propagation segment historically delivers lower revenue in the summer and fall months, with 25% to 35% of its revenue earned in the second half of the calendar year, suggesting potential seasonal volatility.
Cash Position and Debt Risks: Despite a strong cash position of $180.2 million, the Bevo business carries $57.9 million in nonrecourse debt, which could pose risks to financial stability if not managed properly.
ACB FAQs
How does ACB typically perform around its earnings report dates?
Is Aurora Cannabis Inc (ACB) Q3 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ACB Earning Call Sentiment
Aurora Cannabis Inc. (NASDAQ:ACB) Q3 2025 Earnings Call Transcript
ACB.O
-7.14%Positive
Aurora Cannabis has shown strong financial performance with a 37% increase in net revenue, positive free cash flow, and no cannabis business debt. The company is expanding internationally, particularly in favorable regulatory environments like Europe and Australia, and maintains high margins. While there are supply chain and competitive pressures, Aurora's strategic focus on operational excellence and profitability is reassuring. The Q&A session revealed confidence in managing supply challenges and sustaining margins, contributing to a positive outlook. Despite some uncertainties in competition and data, the overall sentiment is positive, suggesting a likely stock price increase.
